spacer
home > pmps > summer 2002 > providing global access to medicines - the role of manufacture and supply
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Providing Global Access to Medicines - The Role of Manufacture and Supply

A universally held objective is patient 'access' to health care interventions in general and medicines in particular - both patent-protected and generic. This represents a particular problem for patients in developing countries, many of whom (for a variety of reasons) do not currently have access. The barriers are multi-factorial: physical and health care infrastructures are often inadequate; financial resources are limited; military, social and political issues abound and country economic policies can have negative effects on health care provision. It is clear that these problems cannot be solved by initiatives in manufacture and supply (M&S), but at the same time some attention has been focused on whether local production, generic competition and technology transfer might make a significant contribution.

Unfortunately, much of the policy discussion within this area has been undertaken without an understanding or appreciation of modern pharmaceutical M&S. This article describes some of the key considerations, and highlights the access-related policy implications. There are five principal considerations, which largely apply equally to branded products and generics:


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By David Webber, Fellow and Director of Economic Policy at the International Federation of Pharmaceutical Manufacturers Associations (IFPMA) Dr David Webber is a Fellow and Director of Economic Policy at the International Federation of Pharmaceutical Manufacturers Associations (IFPMA) in Geneva. David gained a degree in Biology and a PhD in Animal Physiology from London University, and then undertook postdoctoral research, which led to published papers on stomach function.
He joined Glaxo Pharmaceuticals in 1982, and was responsible for various marketing functions in the UK Operating Company, before assuming a role in the corporate strategy unit. In 1999, David was appointed Public Policy Director in the Corporate Policy and Public Affairs group. In 2000, David was seconded to IFPMA, where he is responsible for policy development in key areas for the industry.

spacer
David Webber
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera announces a better drug deposition with RetroNose to enhance therapeutic efficacy of nasal treatments

After announcing a partnership with the Research Center for Respiratory Diseases (CEPR) of Inserm/University of Tours in April 2017, Nemera is happy to publish enhanced drug deposition results compared to classic nasal sprays with RetroNose.
More info >>

White Papers

EU GDP Guidelines: Implications for Shipping Clinical Materials into the European Market

PCI Pharma Services

Recently, the UKís Medicines and Healthcare products Regulatory Agency (MHRA) opened an investigation into a patient complaint of mold on paracetamol (acetaminophen) tablets (1). It discovered the product was shipped by sea from India to multiple companies in the UK at temperatures reaching up to 60 degrees Celsius. Labeling for paracetamol tablets typically states they should be kept below 30 degrees Celsius. In addition, MHRA discovered the humidity levels exceeded 80 percent during shipping, which is too high for the packaging that was used.
More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Irelandís premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement